 Cecilia Low Wang
Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperglycemia | 10 | 2025 | 381 | 2.620 |
Why?
| | Diabetes Mellitus, Type 2 | 21 | 2026 | 2627 | 2.500 |
Why?
| | Blood Glucose | 18 | 2025 | 2359 | 2.070 |
Why?
| | Cardiovascular Diseases | 12 | 2026 | 2218 | 1.640 |
Why?
| | Blood Glucose Self-Monitoring | 7 | 2025 | 703 | 1.630 |
Why?
| | Prediabetic State | 4 | 2026 | 251 | 1.550 |
Why?
| | Diabetes Mellitus | 8 | 2025 | 1107 | 1.310 |
Why?
| | Lower Extremity | 4 | 2024 | 452 | 1.100 |
Why?
| | Hypoglycemic Agents | 11 | 2026 | 1415 | 1.080 |
Why?
| | Metabolic Syndrome | 5 | 2026 | 365 | 1.010 |
Why?
| | Cardiovascular System | 2 | 2019 | 139 | 0.980 |
Why?
| | Cardio-Renal Syndrome | 4 | 2026 | 20 | 0.940 |
Why?
| | Peripheral Arterial Disease | 4 | 2024 | 510 | 0.920 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2024 | 499 | 0.860 |
Why?
| | Community Health Workers | 1 | 2025 | 93 | 0.790 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 448 | 0.640 |
Why?
| | Cardiology | 4 | 2026 | 364 | 0.610 |
Why?
| | Hypoglycemia | 2 | 2025 | 489 | 0.600 |
Why?
| | Epidemics | 1 | 2021 | 96 | 0.600 |
Why?
| | Aspirin | 2 | 2024 | 406 | 0.590 |
Why?
| | Insulin Resistance | 7 | 2024 | 1253 | 0.560 |
Why?
| | Drug Approval | 1 | 2019 | 93 | 0.560 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 210 | 0.550 |
Why?
| | Early Termination of Clinical Trials | 1 | 2018 | 18 | 0.550 |
Why?
| | Glucocorticoids | 3 | 2022 | 537 | 0.540 |
Why?
| | Sample Size | 1 | 2018 | 124 | 0.530 |
Why?
| | Insulin | 12 | 2025 | 2526 | 0.510 |
Why?
| | Algorithms | 3 | 2026 | 1868 | 0.510 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1072 | 0.490 |
Why?
| | Atherosclerosis | 3 | 2017 | 411 | 0.480 |
Why?
| | Ischemia | 1 | 2018 | 424 | 0.450 |
Why?
| | Drugs, Investigational | 1 | 2015 | 31 | 0.440 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 42 | 0.440 |
Why?
| | Hospitals | 2 | 2017 | 740 | 0.430 |
Why?
| | Patient Care Planning | 1 | 2016 | 171 | 0.420 |
Why?
| | Primary Prevention | 2 | 2026 | 228 | 0.410 |
Why?
| | Patient Selection | 1 | 2018 | 746 | 0.390 |
Why?
| | Endocrinology | 2 | 2026 | 77 | 0.390 |
Why?
| | Humans | 47 | 2026 | 147306 | 0.380 |
Why?
| | Swine, Miniature | 1 | 2013 | 89 | 0.380 |
Why?
| | Endovascular Procedures | 1 | 2018 | 395 | 0.380 |
Why?
| | Insulin, Long-Acting | 2 | 2024 | 65 | 0.370 |
Why?
| | Clinical Decision-Making | 2 | 2026 | 367 | 0.370 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 381 | 0.350 |
Why?
| | Obesity | 7 | 2026 | 3149 | 0.320 |
Why?
| | Glucose | 3 | 2024 | 1051 | 0.300 |
Why?
| | Hospitalization | 3 | 2025 | 2496 | 0.300 |
Why?
| | Insulin, Isophane | 2 | 2024 | 22 | 0.300 |
Why?
| | Enteral Nutrition | 3 | 2024 | 218 | 0.290 |
Why?
| | Diabetes Complications | 2 | 2013 | 225 | 0.250 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2007 | 450 | 0.230 |
Why?
| | Risk Factors | 8 | 2026 | 11017 | 0.230 |
Why?
| | American Heart Association | 4 | 2026 | 363 | 0.210 |
Why?
| | Intensive Care Units | 3 | 2025 | 928 | 0.210 |
Why?
| | United States | 10 | 2026 | 16313 | 0.210 |
Why?
| | Dietary Fats | 3 | 2012 | 309 | 0.200 |
Why?
| | Middle Aged | 15 | 2025 | 36821 | 0.200 |
Why?
| | Aged | 10 | 2025 | 26516 | 0.200 |
Why?
| | Male | 20 | 2025 | 73954 | 0.190 |
Why?
| | Female | 21 | 2025 | 80081 | 0.190 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2006 | 274 | 0.180 |
Why?
| | Heart Failure | 1 | 2016 | 2334 | 0.180 |
Why?
| | Glucose Intolerance | 1 | 2024 | 142 | 0.180 |
Why?
| | Factor Xa Inhibitors | 1 | 2024 | 194 | 0.180 |
Why?
| | Life Style | 1 | 2025 | 504 | 0.180 |
Why?
| | Rivaroxaban | 1 | 2024 | 271 | 0.180 |
Why?
| | Diet | 3 | 2015 | 1284 | 0.170 |
Why?
| | Treatment Outcome | 5 | 2019 | 11947 | 0.170 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 88 | 0.170 |
Why?
| | Steroids | 1 | 2022 | 162 | 0.170 |
Why?
| | Dyslipidemias | 1 | 2023 | 185 | 0.170 |
Why?
| | Patient Admission | 1 | 2012 | 220 | 0.160 |
Why?
| | Anticholesteremic Agents | 2 | 2017 | 157 | 0.160 |
Why?
| | Postoperative Complications | 2 | 2024 | 3022 | 0.150 |
Why?
| | Dexamethasone | 1 | 2022 | 368 | 0.150 |
Why?
| | Rural Population | 1 | 2025 | 685 | 0.150 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 1998 | 55 | 0.150 |
Why?
| | Diet, Reducing | 2 | 1998 | 91 | 0.150 |
Why?
| | Pilot Projects | 1 | 2025 | 1912 | 0.140 |
Why?
| | Diabetic Angiopathies | 1 | 2011 | 267 | 0.140 |
Why?
| | Dietary Carbohydrates | 4 | 2012 | 147 | 0.140 |
Why?
| | Inpatients | 1 | 2012 | 556 | 0.130 |
Why?
| | Risk Assessment | 3 | 2026 | 3784 | 0.130 |
Why?
| | Double-Blind Method | 2 | 2024 | 2080 | 0.130 |
Why?
| | Critical Illness | 1 | 2024 | 907 | 0.130 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 357 | 0.120 |
Why?
| | Hypercholesterolemia | 1 | 2017 | 95 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2015 | 2030 | 0.120 |
Why?
| | Colorado | 2 | 2025 | 4591 | 0.120 |
Why?
| | Insulin Receptor Substrate Proteins | 2 | 2013 | 55 | 0.120 |
Why?
| | Early Growth Response Protein 1 | 1 | 2006 | 32 | 0.120 |
Why?
| | Diet, Diabetic | 1 | 1996 | 33 | 0.120 |
Why?
| | Quality of Health Care | 1 | 2021 | 697 | 0.120 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 80 | 0.110 |
Why?
| | Electronic Health Records | 1 | 2023 | 1214 | 0.110 |
Why?
| | Nausea | 1 | 2015 | 112 | 0.110 |
Why?
| | Mexican Americans | 1 | 2015 | 119 | 0.110 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2004 | 49 | 0.100 |
Why?
| | Caloric Restriction | 2 | 2012 | 133 | 0.100 |
Why?
| | Hypertension | 1 | 2023 | 1280 | 0.100 |
Why?
| | Physicians | 1 | 2023 | 961 | 0.100 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 308 | 0.100 |
Why?
| | Adiponectin | 1 | 2015 | 244 | 0.100 |
Why?
| | Dehydroepiandrosterone | 1 | 2004 | 49 | 0.100 |
Why?
| | Lactic Acid | 1 | 2015 | 295 | 0.100 |
Why?
| | Biomarkers | 3 | 2023 | 4354 | 0.100 |
Why?
| | Quality of Life | 2 | 2023 | 3246 | 0.090 |
Why?
| | Signal Transduction | 4 | 2012 | 5272 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3448 | 0.090 |
Why?
| | Androgens | 1 | 2004 | 181 | 0.090 |
Why?
| | Cystic Fibrosis | 1 | 2012 | 1171 | 0.090 |
Why?
| | Sirtuin 1 | 1 | 2012 | 35 | 0.090 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2013 | 203 | 0.090 |
Why?
| | C-Peptide | 3 | 2026 | 191 | 0.090 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 103 | 0.090 |
Why?
| | Muscle, Skeletal | 2 | 2012 | 1798 | 0.090 |
Why?
| | Disease Management | 1 | 2016 | 654 | 0.090 |
Why?
| | Phosphorylation | 2 | 2013 | 1721 | 0.090 |
Why?
| | Postmenopause | 1 | 2004 | 394 | 0.090 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2026 | 3952 | 0.080 |
Why?
| | Arteries | 1 | 2013 | 262 | 0.080 |
Why?
| | Weight Loss | 2 | 1998 | 867 | 0.080 |
Why?
| | Estrogens | 1 | 2004 | 368 | 0.080 |
Why?
| | Prospective Studies | 4 | 2025 | 8166 | 0.080 |
Why?
| | Adiposity | 1 | 2015 | 533 | 0.080 |
Why?
| | Renal Insufficiency | 1 | 2013 | 172 | 0.080 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2012 | 192 | 0.080 |
Why?
| | Swine | 1 | 2013 | 828 | 0.080 |
Why?
| | Patient Care Team | 1 | 2016 | 712 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2024 | 17561 | 0.080 |
Why?
| | Vasodilation | 1 | 2013 | 522 | 0.070 |
Why?
| | Oxidative Stress | 1 | 2006 | 1368 | 0.070 |
Why?
| | Adult | 10 | 2026 | 41406 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2013 | 467 | 0.070 |
Why?
| | Practice Guidelines as Topic | 2 | 2026 | 1598 | 0.070 |
Why?
| | Insulin Infusion Systems | 2 | 2012 | 488 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2625 | 0.060 |
Why?
| | Latent Autoimmune Diabetes in Adults | 1 | 2026 | 3 | 0.060 |
Why?
| | Phosphates | 1 | 2007 | 177 | 0.060 |
Why?
| | Review Literature as Topic | 1 | 2026 | 53 | 0.060 |
Why?
| | Cognition | 1 | 2004 | 1286 | 0.060 |
Why?
| | Cholesterol, LDL | 2 | 2017 | 363 | 0.050 |
Why?
| | Endocrinologists | 1 | 2023 | 12 | 0.050 |
Why?
| | Nonlinear Dynamics | 1 | 2023 | 95 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2024 | 361 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2004 | 1302 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4605 | 0.040 |
Why?
| | Injections, Subcutaneous | 1 | 2012 | 170 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2026 | 1518 | 0.040 |
Why?
| | Insulin Glargine | 1 | 2012 | 88 | 0.040 |
Why?
| | Albuminuria | 1 | 2012 | 189 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2024 | 289 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2024 | 1046 | 0.040 |
Why?
| | Frailty | 1 | 2024 | 206 | 0.040 |
Why?
| | Vascular Surgical Procedures | 1 | 2024 | 347 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2012 | 383 | 0.040 |
Why?
| | Phenotype | 2 | 2023 | 3216 | 0.040 |
Why?
| | Calcium | 1 | 2007 | 1197 | 0.040 |
Why?
| | Cells, Cultured | 3 | 2007 | 4170 | 0.040 |
Why?
| | Animals | 5 | 2013 | 38417 | 0.040 |
Why?
| | Critical Care | 1 | 2025 | 705 | 0.040 |
Why?
| | Adolescent | 2 | 2015 | 22826 | 0.040 |
Why?
| | Autoantibodies | 1 | 2026 | 1513 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2012 | 522 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2024 | 8432 | 0.030 |
Why?
| | Global Health | 1 | 2021 | 406 | 0.030 |
Why?
| | Overweight | 1 | 2023 | 617 | 0.030 |
Why?
| | Dietary Fats, Unsaturated | 1 | 1998 | 24 | 0.030 |
Why?
| | Cholesterol | 2 | 1998 | 410 | 0.030 |
Why?
| | Exercise Therapy | 1 | 2012 | 489 | 0.030 |
Why?
| | Mass Screening | 1 | 2026 | 1375 | 0.030 |
Why?
| | Triglycerides | 2 | 1998 | 529 | 0.030 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 822 | 0.030 |
Why?
| | Plaque, Atherosclerotic | 1 | 2017 | 61 | 0.030 |
Why?
| | Lipoproteins | 1 | 1998 | 166 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 2110 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2006 | 16 | 0.030 |
Why?
| | Young Adult | 3 | 2015 | 14437 | 0.030 |
Why?
| | Diet Surveys | 1 | 2015 | 91 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 136 | 0.030 |
Why?
| | Primary Health Care | 1 | 2026 | 1760 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 1996 | 202 | 0.030 |
Why?
| | Glucagon | 1 | 1996 | 114 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 219 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 264 | 0.030 |
Why?
| | Time Factors | 2 | 2006 | 7173 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2954 | 0.030 |
Why?
| | Hyperinsulinism | 1 | 2004 | 115 | 0.020 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2003 | 85 | 0.020 |
Why?
| | Androstadienes | 1 | 2003 | 77 | 0.020 |
Why?
| | Rats | 2 | 2007 | 5613 | 0.020 |
Why?
| | Helminthiasis | 1 | 1993 | 11 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 1996 | 1281 | 0.020 |
Why?
| | Lipids | 1 | 1998 | 723 | 0.020 |
Why?
| | Reference Values | 1 | 2004 | 800 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 288 | 0.020 |
Why?
| | Interleukin-4 | 1 | 1993 | 207 | 0.020 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 199 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2021 | 5478 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2003 | 1049 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2012 | 135 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 1005 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 1993 | 316 | 0.020 |
Why?
| | PPAR gamma | 1 | 2012 | 182 | 0.020 |
Why?
| | Self Report | 1 | 2015 | 887 | 0.020 |
Why?
| | Cattle | 1 | 2003 | 948 | 0.020 |
Why?
| | Psychomotor Performance | 1 | 2004 | 326 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1514 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1186 | 0.020 |
Why?
| | Interferon-gamma | 1 | 1993 | 786 | 0.020 |
Why?
| | Cell Movement | 1 | 2003 | 966 | 0.020 |
Why?
| | Transcription Factor Pit-1 | 1 | 2007 | 26 | 0.020 |
Why?
| | Sodium-Phosphate Cotransporter Proteins | 1 | 2007 | 10 | 0.020 |
Why?
| | Gene Expression | 1 | 2012 | 1481 | 0.020 |
Why?
| | Risk | 1 | 2007 | 927 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 6011 | 0.010 |
Why?
| | Kinetics | 1 | 2007 | 1569 | 0.010 |
Why?
| | Apolipoproteins | 1 | 1998 | 38 | 0.010 |
Why?
| | Regression Analysis | 1 | 1998 | 1003 | 0.010 |
Why?
| | Energy Intake | 1 | 1998 | 514 | 0.010 |
Why?
| | Antigens, Helminth | 1 | 1993 | 16 | 0.010 |
Why?
| | Acute Disease | 1 | 1993 | 1049 | 0.000 |
Why?
| | Chronic Disease | 1 | 1993 | 1845 | 0.000 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1993 | 1162 | 0.000 |
Why?
|
|
Low Wang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|